• 1
    Garnero P, Darte C, Delmas PD 1999 A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24: 603609.
  • 2
    Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12: 10831091.
  • 3
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11: 337349.
  • 4
    Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP 1994 Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study. J Bone Miner Res 9: 14331440.
  • 5
    Schlemmer A, Hassager C, Delmas PD, Christiansen C 1994 Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol (Oxf) 40: 777782.
  • 6
    Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG 1993 Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3: 255260.
  • 7
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C 1999 Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84: 23632368.
  • 8
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24: 237244.
  • 9
    Chesnut CH III, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ 1997 Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102: 2937.
  • 10
    Delmas PD, Hardy P, Garnero P, Dain M 2000 Monitoring individual response to hormone replacement therapy with bone markers. Bone 26: 553560.
  • 11
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13: 14311438.
  • 12
    Riggs BL, Melton LJ III, O'Fallon WM 1996 Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18: 197S201S.
  • 13
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 917.
  • 14
    Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11: 434442.
  • 15
    Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM 1998 Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): A randomized controlled trial. JAMA 280: 10671073.
  • 16
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 30693076.
  • 17
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • 18
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312321.
  • 19
    Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16: 18891905.
  • 20
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, Jergas MD, Andriano KN, Cummings SR, Genant HK 1996 Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts. J Bone Miner Res 11: 626637.
  • 21
    Marcus R, Wang O, Satterwhite J, Mitlak B 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18: 1823.
  • 22
    Heathman MA, Melnick K, O'Brien L, Gaich G, Satterwhite J 2000 Evaluation of biochemical markers of bone formation and resorption as early indicators of bone mineral density response to LY333334 [recombinant human parathyroid hormone (1–34)] therapy. AAPS PharmSci 2: 1811.
  • 23
    Krege J, Heathman M, Reginster J, Satterwhite J 2003 Increases in serum-terminal propeptide of type I collagen with terparatide treatment predict increases in lumbar spine bone density. Program and Abstracts The Endocrine Society's 85th Annual Meeting, New Orleans, LA, USA, June 19–22, 2003.
  • 24
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922930.
  • 25
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34: 344351.
  • 26
    Sarkar S, Reginster JY, Crans G, Diez-Perez A, Pinette K, Delmas P 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394401.
  • 27
    Bauer DC, Black D, Garnero P, Hochberg M, Ott SM, Schneider DL, Thompson D, Orloff J, Ewing S, Delmas P 2004 Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial. Osteoporos Int 13: S521.
  • 28
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 10511056.